Citations

Clear

948 citation(s) found for "Li, Bryan".

O1‐11‐04: CARDIOVASCULAR RISK FACTORS AND THEIR INTERACTIONS AMONG CLINICALLY DEFINED NEURODEGENERATIVE DISEASES
Malek‐Ahmadi, Michael , Monsell, Sarah E. , Woodruff, Bryan K. , Reiman, Eric M. , Wilson, Jeffrey R. , Dugger, Brittany N. , Kukull, Walter A.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2014.04.119 Get It

P2‐380: ABSENCE OF A “WIDOWHOOD EFFECT” ON INCIDENCE OF DEMENTIA IN COGNITIVELY NORMAL RESEARCH SUBJECTS
Woodruff, Bryan K. , Stonnington, Cynthia M. , Hentz, Joseph G. , Wojtulewicz, L, Caselli, Richard J. , Locke, Dona E.C. , Dueck, Amylou C. , Geda, Yonas E.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2014.05.1060 Get It

P2‐379: PARADOXICAL IMPACT OF WIDOWHOOD ON INCIDENCE OF DEMENTIA IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT
Woodruff, Bryan K. , Stonnington, Cynthia M. , Hentz, Joseph G. , Wojtulewicz, L, Geda, Yonas E., Caselli, Richard J. , Locke, Dona E.C. , Dueck, Amylou C.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2014.05.1059 Get It

Abstract LB-296: FDG-PET avidity negatively impacts survival in pStage I NSCLC in the ACOSOG Z4031 trial.
Grogan, Eric L. , Deppen, Stephen A. , Chen, Heidi , Ballman, Karla V. , Verdial, Francys C. , Aldrich, Melinda C. , Decker, Paul A. , Harpole, David H., Cerfolio, Robert J. , D’Amico, Thomas A., Shrager, Joseph B. , Meyers, Bryan F., Decker, Paul A. , Keenan, Robert J. , Jones, David R. , Meyers, Bryan F. , Putnam, Joe B. , Ballman, Karla

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: LB-296-LB-296

10.1158/1538-7445.am2013-lb-296 Get It

Abstract Background: Fluoro-deoxyglucose positron emission tomography (FDG-PET) scans are used for diagnosis and staging of known or suspected non-small cell lung cancer (NSCLC). Single institution studies examining the impact of avidity on survival have reported mixed results. The purpose of this study is to evaluate the association between FDG-PET avidity and survival in the national prospective ACOSOG Z4031 trial in patients with pathological Stage I NSCLC. Methods: Between 2004 and 2006, 1074 patients with known or suspected clinical stage I (cT1-2N0M0) NSCLC were enrolled in the ACOSOG Z4031 trial and underwent surgical resection. FDG-PET results were abstracted from radiology interpretations included in the case report forms. FDG-PET avidity was categorized based on either radiologist description or reported maximum standard uptake value (SUV). The four categories were: 1) not avid and not cancerous (SUV=0), 2) low avidity and likely not cancerous (SUV>0 and <2.5), 3) avid and probably cancerous (SUV≥2.5 and <5) and 4) highly avid and likely cancerous (SUV≥5). The lesion was classified as avid if in categories 3 or 4. The final diagnosis was determined by pathological examination and all cause mortality was reported. Cox proportional hazard regression was used to assess the impact of FDG-PET avidity on survival. The covariates used in the model included pStage, gender, age, race, and preoperative lesion size. Kaplan-Meier survival curves were calculated and the log-rank test was used to determine differences in survival based on FDG-PET avidity. Results: There were 51 enrolling sites in 39 cities with 969 eligible participants. Preoperative FDG-PET results were available for 540 participants with NSCLC and 81% had FDG-PET avid or highly avid lesions. 400 patients had pStage I NSCLC and the 5 year survival was 70% with 95%CI (65%, 75%). FDG-PET avidity, male gender, age, and lesion size negatively impacted survival. FDG-PET avidity in pStage I disease still negatively impacted survival (p=0.03) when controlling for lesion size. The 5 year survival for Stage I disease was 80% with 95%CI (68%, 88%) in FDG-PET negative patients and 67% with 95% CI (61%, 72%) in FDG-PET positive patients (p=0.02). Conclusions: In a national surgical population with pathological stage I NSCLC, FDG-PET avidity negatively impacted five year survival, independently of lesion size. Further work should be done to determine if chemotherapy would be beneficial in patients with PET avid lesions and pStage I NSCLC. Citation Format: Eric L. Grogan, Stephen A. Deppen, Heidi Chen, Karla V. Ballman, Francys C. Verdial, Melinda C. Aldrich, Paul A. Decker, David H. Harpole, Robert J. Cerfolio, Robert J. Keenan, David R. Jones, Thomas A. D'Amico, Joseph B. Shrager, Bryan F. Meyers, Joe B. Putnam. FDG-PET avidity negatively impacts survival in pStage I NSCLC in the ACOSOG Z4031 trial. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-296. doi:10.1158/1538-7445.AM2013-LB-296
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer
Landreneau, Rodney J., Mandrekar, Sumithra J. , Nichols, Francis C., Hillman, Shauna L., Heron, Dwight E. , Meyers, Bryan F., DiPetrillo, Thomas A., Jones, David R. , Tan, Angelina D., Daly, Benedict D.T., Putnam, Joe B. , Fernando, Hiran C. , Starnes, Sandra L, Meyers, Bryan F. , Starnes, Sandra Lynne , Jones, David R

Mayo Clinic

Journal of Clinical Oncology | July 1, 2014 | Volume: 32 | Issue: 23 | Pages: 2456-2462

10.1200/jco.2013.53.4115 | PMID 24982457 Get It

Purpose A major concern with sublobar resection (SR) for non–small-cell lung cancer (NSCLC) is high local recurrence (LR). Adjuvant brachytherapy may reduce LR This multicenter randomized trial compares SR to SR with brachytherapy (SRB). Patients and Methods High-risk operable patients with NSCLC ≤ 3 cm were randomly assigned to SR or SRB. The primary end point was time to LR, where LR included recurrence at the staple line (local progression), in the primary tumor lobe away from the staple line, and in ipsilateral hilar nodes. The trial was designed to have a 90% power to detect a hazard ratio (HR) of 0.315 in favor of SRB, using a one-sided type I error rate of 0.05 with a sample size of 100 eligible patients in each arm. Results Two hundred twenty-four patients were randomly assigned; 222 patients were evaluable for intent-to-treat analysis. Median age was 71 years (range, 49 to 87 years). No differences were found in baseline characteristics. Median follow-up time was 4.38 years (range, 0.04 to 5.59 years). There was no difference in time to LR (HR, 1.01; 95% CI, 0.51 to 1.98; log-rank P = .98) or in the types of LR. Local progression occurred in only 17 (7.7%) of 222 patients. In patients with potentially compromised margins (margin < 1 cm, margin-to-tumor ratio < 1, positive staple line cytology, wedge resection, nodule size > 2.0 cm), SRB did not reduce LR, although trends favored the SRB arm. This was most marked in 14 patients with positive staple line cytology (HR, 0.22; P = .24). Three-year overall survival rates were similar for patients in the SR (71%) and SRB (71%) arms (P = .97). Conclusion Brachytherapy did not reduce LR after SR. This finding may have been related to closer attention to parenchymal margins by surgeons participating in this study.
An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules
McIver, Bryan, Castro, M. Regina , Bernet, Victor , Smallridge, Robert C., Henry, Michael , Kosok, Laura, Morris, John C. , Reddi, Honey V.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 29, 2014 | Volume: 99 | Issue: 11 | Pages: 4069-4077

10.1210/jc.2013-3584 | PMID 24780044 Get It

Context: Molecular markers hold the promise of improved diagnostic yield in thyroid fine-needle biopsy. The Afirma gene expression classifier (GEC), available commercially, reports a negative predictive value of 94% in the diagnosis of benign nodules after indeterminate cytology. However, there are currently no independent studies of the performance of this assay. Objective: The aim was to assess the performance of the Afirma GEC in an academic medical center. Design: Samples for the GEC were collected according to the manufacturer's recommended protocol from patients undergoing thyroid fine-needle aspiration. We requested GEC analysis on nodules reported cytologically as follicular neoplasm or atypia or follicular lesion of undetermined significance from patients willing to defer surgery. Patients: All patients undergoing thyroid fine-needle aspiration during the study period, whose cytology was reported as follicular neoplasm or atypia of undetermined significance/follicular lesion of undetermined significance, were offered access to the test and recruited to this study. Intervention: Patients whose GEC was “benign” were offered ultrasound follow-up in lieu of surgery. Those with a “suspicious” GEC were advised to undergo diagnostic lobectomy. Setting: The study was conducted at a large academic medical center. Main Outcome Measure: We measured the rate of benign and suspicious calls from the Afirma GEC and histological diagnosis after surgery. Results: A total of 72 nucleic acid samples were sent for GEC analysis. In 12 (17%) of these samples, there was insufficient mRNA, leaving 60 Afirma results for analysis. Of these, 16 (27%) were benign, whereas 44 (73%) were suspicious. The rate of confirmed malignancy in GEC-suspicious nodules was only 17%. Conclusion: The Afirma GEC demonstrates a lower than expected rate of benign reports in follicular or Hürthle cell neoplasm and a lower than anticipated malignancy rate within GEC-suspicious nodules. These data suggest that the positive predictive value of the GEC is lower than previously reported and call into question the performance of the test when applied in the context of specialized academic cytopathology.
Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma
Gustafson, Heather L., Goldman, Bryan, Spier, Catherine, Cerhan, James R. , Link, Brian K. , Maurer, Matthew J. , Persky, Daniel O. , Miller, Thomas P. , Fisher, Richard I., Briehl, Margaret M., Yao, Song , Lee, Kristy , LeBlanc, Michael , Rimsza, Lisa M. , Habermann, Thomas M. , Slager, Susan L. , Ambrosone, Christine B. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

American Journal of Hematology | March 14, 2014 | Volume: 89 | Issue: 6 | Pages: 639-645

10.1002/ajh.23709 | PMID 24633940 Get It

Variable survival outcomes are seen following treatment for aggressive non‐Hodgkin lymphoma (NHL). This study examined whether outcomes for aggressive B‐cell NHL are associated with single nucleotide polymorphisms (SNPs) in oxidative stress‐related genes, which can alter drug metabolism and immune responses. Genotypes for 53 SNPs in 29 genes were determined for 337 patients given anthracycline‐based therapies. Their associations with progression‐free survival (PFS) and overall survival (OS) were estimated by Cox proportional hazard regression; associations with hematologic toxicity were estimated by logistic regression. To validate the findings, the top three SNPs were tested in an independent cohort of 572 DLBCL patients. The top SNPs associated with PFS in the discovery cohort were the rare homozygotes for MPO rs2243828 (hazard ratio [HR] = 1.87, 95% confidence interval [CI] = 1.14–3.06, P = 0.013), AKR1C3 rs10508293 (HR = 2.09, 95% CI = 1.28–3.41, P = 0.0032) and NCF4 rs1883112 (HR = 0.66, 95% CI = 0.43–1.02, P = 0.06). The association of the NCF4 SNP with PFS was replicated in the validation dataset (HR = 0.66, 95% CI = 0.44–1.01, P = 0.05) and the meta‐analysis was significant (HR = 0.66, 95% CI = 0.49–0.89, P < 0.01). The association of the MPO SNP was attenuated in the validation dataset, while the meta‐analysis remained significant (HR = 1.64, 95% CI = 1.12–2.41). These two SNPs showed similar trends with OS in the meta‐analysis (for NCF4, HR = 0.72, 95% CI = 0.51–1.02, P = 0.07 and for MPO, HR = 2.06, 95% CI = 1.36–3.12, P < 0.01). In addition, patients with the rare homozygote of the NCF4 SNP had an increased risk of hematologic toxicity. We concluded that genetic variations in NCF4 may contribute to treatment outcomes for patients with aggressive NHL. Am. J. Hematol. 89:639–645, 2014. © 2014 Wiley Periodicals, Inc.
A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
Bible, Keith C. , Molina, Julian R. , Smallridge, Robert C., Maples, William J., Menefee, Michael E., Rubin, Joseph, Karlin, Nina J. , Sideras, Kostandinos , McIver, Bryan, Fatourechi, Vahab , Burton, Jill K., Webster, Kevin, Bieber, Carolyn, Traynor, Anne M. , Flynn, Patrick J. , Isham, Crescent R., Harris, Pamela Jo , Erlichman, Charles , Suman, Vera J. , Morris, John C. , Hay, Ian , Goh, Boon Cher , Sideras, Kostandinos

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 10, 2014 | Volume: 99 | Issue: 5 | Pages: 1687-1693

10.1210/jc.2013-3713 | PMID 24606083 Get It

Synovial Cyst Mimicking an Intraspinal Sacral Mass
Hoover, Jason M. , Pirris, Stephen M. , Hoover, Jason , Pirris, Stephen

Mayo Clinic

Case Reports in Neurological Medicine | March 4, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-4

10.1155/2014/953579 | PMID 24716025 Get It

A 68-year-old female had a three-week history of severe low back pain radiating down the posterior left buttocks and left leg exacerbated by standing and walking. Lumbar spine MRI revealed cystic mass with similar intensity to cerebrospinal fluid located on dorsolateral left side of the sacral spinal canal inferior to the S1 pedicle. There was compression of left exiting S1 and traversing S2 nerve roots. Neurosurgery consult was requested to evaluate the cystic mass in the sacral spinal canal. After clinical evaluation, an unusually located synovial cyst was thought possible. Cyst contents were heterogeneous, suggestive of small hemorrhage and acute clinical history seemed reasonable. Left S1 and partial left S2 hemilaminectomy was performed and an epidural, partially hemorrhagic cyst was removed. There was no obvious connection to the ipsilateral L5-S1 facet joint. Pathology revealed synovial cyst, and the patient’s leg pain was improved postoperatively. This synovial cyst was unusual as it had no connection with the facet joint intraoperatively and its location in the sacral canal was uncommon.
Chronic subthreshold subdural cortical stimulation for the treatment of focal epilepsy originating from eloquent cortex
Child, Nicholas D., Stead, Matt, Nickels, Katherine , Wetjen, Nicholas M. , Lee, Kendall H. , Klassen, Bryan T. , Wirrell, Elaine , Nickels, Katherine C

Mayo Clinic

Epilepsia | February 26, 2014 | Volume: 55 | Issue: 3 | Pages: No page available

10.1111/epi.12525 | PMID 24571166 Get It

SummaryMedically refractory epilepsy remains a major medical problem worldwide. Although some patients are eligible for surgical resection of seizure foci, a proportion of patients are ineligible for a variety of reasons. One such reason is that the foci reside in eloquent cortex of the brain and therefore resection would result in significant morbidity. This retrospective study reports our experience with a novel neurostimulation technique for the treatment of these patients. We identified three patients who were ineligible for surgical resection of the intracranially identified seizure focus because it resided in eloquent cortex, who underwent therapeutic trial of focal cortical stimulation delivered through the subdural monitoring grid. All three patients had a significant reduction in seizures, and two went on to permanent implantation, which resulted in long‐term reduction in seizure frequency. In conclusion, this small case report provides some evidence of proof of concept of the role of targeted continuous neocortical neurostimulation in the treatment of medically refractory focal epilepsy, and provides support for ongoing investigations into this treatment modality.A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.